Evidence map›Paper›PMID 39254030›Full record

ArticlePigment cell & melanoma research2025

MetFinder: A Tool for Automated Quantitation of Metastatic Burden in Histological Sections From Preclinical Models.

Alcida Karz, Nicolas Coudray, Erol Bayraktar, Kristyn Galbraith, George Jour, Arman Alberto Sorin Shadaloey, Nicole Eskow, Andrey Rubanov, Maya Navarro, Rana Moubarak and 10 more

Abstract read
In one paragraph

Article in Pigment cell & melanoma research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Alcida KarzDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Nicolas CoudrayApplied Bioinformatics Laboratories, NYU Langone Health, New York, New York, USA.
Erol BayraktarDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Kristyn GalbraithDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
George JourDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Arman Alberto Sorin ShadaloeyDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Nicole EskowDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.ORCID 0000-0003-1048-4769
Andrey RubanovDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Maya NavarroDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Rana MoubarakDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Gillian BaptisteDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Grace LevinsonDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Valeria MezzanoExperimental Pathology Research Laboratory, Division of Advanced Research Technologies, NYU Grossman School of Medicine, New York, New York, USA.
Mark AluExperimental Pathology Research Laboratory, Division of Advanced Research Technologies, NYU Grossman School of Medicine, New York, New York, USA.
Cynthia LoomisDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Daniel LimaResearch Software Engineering Core, Medical Center Information Technology Department, NYU Langone Health, New York, New York, USA.
Adam RubensResearch Software Engineering Core, Medical Center Information Technology Department, NYU Langone Health, New York, New York, USA.
Lucia JilaveanuDepartment of Medicine, Yale University, New Haven, Connecticut, USA.
Aristotelis TsirigosDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.
Eva HernandoDepartment of Pathology, NYU Grossman School of Medicine, New York, New York, USA.

Funding

Vaccine FacilityP30CA016087 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MARK Reid PHILIPS · 1985 to 2026
$83.1M
Project 4P50CA225450 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI OSMAN, IMAN, WEBER, JEFFREY S · 2019 to 2025
$12.5M
Project 3: The Evolving Role of Regional Lymph Nodes in Melanoma ProgressionU54CA263001 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando, Iman Osman · 2022 to 2026
$11.6M
TOOLKIT CoreU54CA261717 · NCI · STANFORD UNIVERSITY · PI Melanie Hayden Gephart · 2021 to 2026
$8.9M
NRSA Training CoreTL1TR001447 · NCATS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI MICOLI, KEITH J. · 2015 to 2025
$5.9M
Training Program in Cell BiologyT32GM136542 · NIGMS · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI SMITH, SUSAN · 2020 to 2024
$3.0M
Role of circular RNA CDR1as in melanomaR01CA243446 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HERNANDO, EVA · 2020 to 2024
$2.7M
Research Training for Physician-Scientists in Gastrointestinal OncologyT32CA193111 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI BAR-SAGI, DAFNA, WOLFGANG, CHRISTOPHER L. · 2015 to 2024
$2.7M
Defining epigenetic regulators of tumor heterogeneity and metastasis in melanomaR01CA274100 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando, Markus Schober · 2022 to 2026
$2.5M
Immune Therapy for Brain MetastasisR01CA269286 · NCI · YALE UNIVERSITY · PI Lucia Beatrice Jilaveanu, Harriet M. Kluger · 2023 to 2026
$2.2M
Developing new therapeutic strategies for brain metastasisR01CA277425 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI Eva Hernando · 2023 to 2026
$2.2M
Metabolic adaptations in melanoma brain metastasisR21CA286244 · NCI · NEW YORK UNIVERSITY SCHOOL OF MEDICINE · PI HERNANDO, EVA · 2024 to 2025
$436k
Congressionally Directed Medical Research Programs, Melanoma Research program, Department of Defense W81XWH-20-MRP-TSANational Center for Advanced Translational Sciences 5TL1TR001447NCATS NIH HHS TL1 TR001447NCI NIH HHS P30 CA016087NCI NIH HHS P30CA016087NCI NIH HHS P50 CA225450NCI NIH HHS R01 CA243446NCI NIH HHS R01CA269286NCI NIH HHS R01 CA274100NCI NIH HHS R01 CA277425NCI NIH HHS R21 CA286244NCI NIH HHS T32 CA193111NCI NIH HHS U54 CA261717NCI NIH HHS U54 CA263001NCI NIH HHS U54CA263001NIGMS NIH HHS T32 GM136542NIH HHS S10 OD021747
6 · The paper itself

Abstract

As efforts to study the mechanisms of melanoma metastasis and novel therapeutic approaches multiply, researchers need accurate, high-throughput methods to evaluate the effects on tumor burden resulting from specific interventions. We show that automated quantification of tumor content from whole slide images is a compelling solution to assess in vivo experiments. In order to increase the outflow of data collection from preclinical studies, we assembled a large dataset with annotations and trained a deep neural network for the quantitative analysis of melanoma tumor content on histopathological sections of murine models. After assessing its performance in segmenting these images, the tool obtained consistent results with an orthogonal method (bioluminescence) of measuring metastasis in an experimental setting. This AI-based algorithm, made freely available to academic laboratories through a web-interface called MetFinder, promises to become an asset for melanoma researchers and pathologists interested in accurate, quantitative assessment of metastasis burden.

Indexed as

Neoplasm MetastasisAlgorithmsAnimalsAutomationCell Line, TumorDisease Models, AnimalHumansImage Processing, Computer-AssistedMelanomaMiceSkin NeoplasmsSoftwareTumor Burdendeep learninghistopathologymetastatic burdenmurine modelspreclinical studiesquantificationwhole slide images

Identifiers

PMID39254030
PMCPMC11948878

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.